
views
OptiBiotix Health and SkinBioTherapeutics – further progress & triggers for dramatic 2022 re-rate
OptiBiotix Health (OPTI) was one of our tips of the year, with we anticipating financial progress as its deals for its compounds expand and further deals kick-in. It has now announced that a further human volunteer study on its cholesterol-reducing probiotic LPLDL - on a different population group of hypercholesterolemic adults - has shown “at six weeks, when volunteers taking placebo were compared to those taking LPLDL, there were statistically significant changes to clinically important cardiovascular risk”, including “34.2% reduction in total cholesterol (p=0.001)”.
- By Tom Winnifrith & Steve Moore
- 2022-01-21 09:02:53